{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-005515","form_type":"8-K","ticker":null,"cik":"0000855654","company_name":"ImmunoGen, Inc.","filed_at":"2023-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.445235+00:00","generated_at":"2026-06-17T05:32:02.548916+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmunoGen secures up to $175M non-dilutive term loan from Pharmakon; $75M drawn at close","bullets":["Initial tranche of $75M funded immediately; second tranche of $50M (expandable to $100M) contingent on MIRASOL trial data and ELAHERE sales threshold.","Loan matures April 2028; interest-only for 36 months (extendable 12 months), then ratable principal payments.","Interest rate: 3-month SOFR (floor 2.75%) + 8.00% per annum.","Proceeds used for general corporate and working capital; loan secured by substantially all assets except certain non-ELAHERE IP.","Goldman Sachs acted as financial advisor to ImmunoGen on the transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-005515","json":"https://secwatch.observer/filing/0001558370-23-005515.json","markdown":"https://secwatch.observer/filing/0001558370-23-005515.md","text":"https://secwatch.observer/filing/0001558370-23-005515.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/855654/000155837023005515/0001558370-23-005515-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/855654/000155837023005515/imgn-20230406x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:32:02.548916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5161ccaef4321ff496ef0af6fd786136013b0fb","claim":"ImmunoGen, Inc. incurred term loan of up to a $175 million senior secured term loan with BioPharma Credit PLC, BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP (funds managed by Pharmakon Advisors, LP) at SOFR subject to a floor of 2.75% per annum, plus 8.00% per annum maturing April 6, 2028.","evidence_excerpt":"On April 6, 2023, ImmunoGen, Inc. (the “Company”) entered into an agreement with BioPharma Credit PLC (the “Collateral Agent”), BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, which are funds managed by Pharmakon Advisors, LP (collectively, “Pharmakon”), and the guarantors party to such agreement (the “Loan Agreement”). The Loan Agreement provides for up to a $175 million senior secured term loan (the “Term Loan”) consisting of two tranches that matures on April 6, 2028.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/855654/000155837023005515/0001558370-23-005515-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"up to a $175 million senior secured term loan"},{"label":"Counterparty","value":"BioPharma Credit PLC, BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP (funds managed by Pharmakon Advisors, LP)"},{"label":"Rate","value":"SOFR subject to a floor of 2.75% per annum, plus 8.00% per annum"},{"label":"Maturity","value":"April 6, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"4a910e57610a5e4693f61d141eda25dfd3e5a7b2","claim":"ImmunoGen, Inc. entered into Loan Agreement with BioPharma Credit PLC, BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP valued at up to $175 million senior secured term loan (effective 2023-04-06).","evidence_excerpt":"On April 6, 2023, ImmunoGen, Inc. (the “Company”) entered into an agreement with BioPharma Credit PLC (the “Collateral Agent”), BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, which are funds managed by Pharmakon Advisors, LP (collectively, “Pharmakon”), and the guarantors party to such agreement (the “Loan Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/855654/000155837023005515/0001558370-23-005515-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"BioPharma Credit PLC, BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP"},{"label":"Value","value":"up to $175 million senior secured term loan"},{"label":"Effective","value":"2023-04-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}